Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 303

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 303
---
 among other things, immediately following the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC, (i) the Denali-Longevity Merger
would occur, with Denali as the surviving entity of the Denali-Longevity Merger, and (ii) the Longevity Merger would occur, with Longevity as the surviving company of the Longevity Merger. Afterwards,
each of Longevity and Denali would be a subsidiary of Holdco, and Holdco would become a publicly traded company.

On January 9, 2024, Denali held the
Longevity Business Combination Meeting and voted in favor of approving the Longevity Business Combination.

On May 13, 2024, according to Section 8.21 of
the Longevity Merger Agreement, the Seller Representative informed Denali management that he received a written notice regarding the termination of one of the Cerevast Acquisition Agreement, the Aegeria Acquisition Agreement, and the Novokera
Acquisition Agreement (each as defined in the Longevity Merger Agreement), with the possibility of rescinding the termination notice subject to the satisfaction of certain conditions. While the Longevity Agreement had not been formally terminated as
of such date, Denali’s management was on notice of such possibility.

On May 30, 2024, Henry Ji, Ph.D., the Executive Chairperson of Semnur and
Scilex, and Lei Huang, the Chief Executive Officer and a director of Denali and the Chief Executive Officer of US Tiger, were initially introduced by Jack Wu, a business partner of US Tiger, at the offices of US Tiger at 437 Madison Ave., New York.

During the meeting, Mr. Ji and Mr. Huang discussed if US Tiger could participate in Scilex’s potential follow-on or PIPE offering. Additionally,
Mr. Huang highlighted other strategic opportunities that US Tiger could facilitate for Semnur and Scilex, including business combination transactions with special purpose acquisition companies for which US Tiger is currently acting as an advisor,
such as Denali.

On June 11, 2024, Dr. Ji attended a video conference call with Mr. Huang and Peter Xu, the Manager of the Sponsor to explore a potential
business combination between Semnur and Denali, in light of the possible termination of the Longevity Merger Agreement.

174

Since Semnur’s inception, Scilex has been